Доступ открыт Открытый доступ  Доступ закрыт Только для подписчиков

Возможности и ограничения применения ингаляционных глюкокортикостероидов в терапии хронической обструктивной болезни легких


https://doi.org/10.18093/0869-0189-2018-28-5-602-612

Полный текст:


Аннотация

Ингаляционные глюкокортикостероиды (иГКС) в сочетании с длительно действующими бронходилататорами (ДДБД) являются одними из основных лекарственных средств для лечения пациентов с хронической обструктивной болезнью легких (ХОБЛ) при отсутствии эффекта на фоне постоянной терапии ДДБД. Установлено, что при включении иГКС в программу терапии больных ХОБЛ риск развития пневмонии увеличивается у пожилых (старше 55 лет) лиц; курильщиков; пациентов с обострениями, пневмониями в анамнезе и индексом массы тела < 25 кг / м2, одышкой или тяжелым ограничением воздушного потока. При назначении больным ХОБЛ иГКС следует учитывать соотношение показателя пользы и риска возникновения возможных нежелательных явлений, особенно у лиц с повышенными факторами риска осложнений, связанных с приемом иГКС.


Об авторе

И. В. Лещенко
Федеральное государственное бюджетное образовательное учреждение высшего образования «Уральский государственный медицинский университет» Министерства здравоохранения Российской Федерации; Общество с ограниченной ответственностью «Медицинское объединение "Новая больница"»
Россия
Лещенко Игорь Викторович – доктор медицинских наук, профессор кафедры фтизиатрии, пульмонологии и торакальной хирургии Федерального государственного бюджетного образовательного учреждения высшего образования «Уральский государственный медицинский университет» Министерства здравоохранения Российской Федерации; научный руководитель клиники ООО «Медицинское объединение "Новая больница"»620028, Екатеринбург, ул. Репина, 3, 620109, Екатеринбург, ул. Заводская, 29


Список литературы

1. Global Initiative for Chronic Obstructive Lung Disease. Pocket Guide to COPD Diagnosis, Management, and Prevention. A Guide for Health Care Professional. 2018 Report. Available at: https://goldcopd.org/wp-content/uploads/2018/02/WMS-GOLD-2018-Feb-Final-to-print-v2.pdf

2. Айсанов З.Р., Авдеев С.Н., Архипов В.В. и др. Национальные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких: алгоритмы принятия клинических решений. Пульмонология. 2017; 27 (1): 13–20. DOI: 10.18093/0869-0189-2017-27-1-13-20.

3. Burge P.S., Calverley P.M., Jones P.W. et al. Randomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. 2000; (320): 1297. DOI: 10.1136/bmj.320.7245.1297.

4. Pauwels R.A., Lofdahl C.G., Laitinen L.A. et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N. Engl. J. Med. 1999; 340 (25): 1948–1953. DOI: 10.1056/NEJM199906243402503.

5. Vestbo J., Sorensen T., Lange P. et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. Lancet. 1999; 353 (9167): 1819–1823. DOI: 10.1016/S0140-6736(98)10019-3.

6. Wise R., Connett J., Weinmann G. et al. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N. Engl. J. Med. 2000; 343 (26): 1902–1909. DOI: 10.1056/NEJM200012283432601.

7. Calverley P., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet. 2003; 361 (9356): 449–456. DOI: 10.1016/S0140-6736(03)12459-2.

8. Rossi A., Guerriero M., Corrado A. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir. Res. 2014; (15): 77. DOI: 10.1186/1465-9921-15-77.

9. Calle Rubio M., Casamor R., Miravitlles M. Identification and distribution of COPD phenotypes in clinical practice according to Spanish COPD Guidelines: the FENEPOC study. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; (12): 2373–2383. DOI: 10.2147/COPD.S137872.

10. Mаntero M., Radovanovic D., Santus P., Blasi F. Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; (13): 2319–2333. DOI: 10.2147/COPD.S147484.

11. Lipson D.A., Barnacle H., Birk R. et al. FULFIL trial: once-daily triple therapy for patients with chronic pulmonary disease. Am. J. Respir. Crit. Care Med. 2017; 196 (4): 438–446. DOI: 10.1164/rccm.201703-0449OC.

12. Singh D., Papi A., Corradi M. et al. Single inhaler triple therapy versus inhaled corticosteroid plus long acting β-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomized controlled trial. Lancet. 2016; 388 (10048): 963–973. DOI: 10.1016/S0140-6736(16)31354-X.

13. Lipson D.A., Barnhart F., Brealey N. et al. IMPACT Investigators Once-daily single-inhaler triple versus dual therapy in patients with COPD. N. Engl. J. Med. 2018; 378 (18): 1671–1680. DOI: 10.1056/NEJMoa1713901.

14. Aaron S.D., Vandemheen K.L., Fergusson D. et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2007; 146 (8): 545–555. DOI: 10.7326/0003-4819-146-8-200704170-00152.

15. Papi A., Vestbo J., Fabbri L. et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomized controlled trial. Lancet. 2018; 391 (1025): 1076–1084. DOI: 10.1016/S0140-6736(18)30206-X.

16. Vestbo J., Papi A., Corradi M. et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomized controlled trial. Lancet. 2017; 389 (10082): 1919–1929. DOI: 10.1016/S0140-6736(17)30188-5.

17. Buhl R., Criée C-P., Kardos P. et al. Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; (13): 2557–2568. DOI: 10.2147/COPD.S169958.

18. Tashkin D.P., Strange C. Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy? Int. J. Chron. Obstruct. Pulmon. Dis. 2018; (13): 2587–2601. DOI: 10.2147/COPD.S172240.

19. Magnussen H., Disse B., Rodriguez-Roisin R. et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N. Engl. J. Med. 2014; 371 (14): 1285–1294. DOI: 10.1056/NEJMoa1407154.

20. Watz H., Tetzlaff K., Wouters E.F. et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir. Med. 2016; 4 (5): 390–398. DOI: 10.1016/S2213-2600(16)00100-4.

21. Cazzola M., Rogliani P., Calzetta L., Matera M.G. Triple therapy versus single and dual long-acting bronchodilator therapy in chronic obstructive pulmonary disease: a systematicreview and meta-analysis. Eur. Respir. J. 2018; 52 (6).DOI:10.1183/13993003.01586-2018.

22. Ohbayashi H., Adachi M. Influence of dentures on residual inhaled corticosteroids in the mouths of elderly asthma patients. Respir. Investig. 2012; 50 (2): 54–61. DOI: 10.1016/j.resinv.2012.05.001.

23. Yang I.A., Fong K.M., Sim E.H. et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2007; (2): CD002991. DOI: 10.1002/14651858.CD002991.pub2.

24. Kurt E., Yildirim H., Kiraz N. et al. Oropharyngeal candidiasis with dry powdered fluticasone propionate: 500/day versus 200 microg/day. Allergol Immunopathol. 2008; 36 (1): 17–20. DOI: 10.1157/13115666.

25. Singh S., Loke Y.K. Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update. Curr. Opin. Pulm. Med. 2010; 16 (2): 118–122. DOI: 10.1097/MCP.0b013e328334c085.

26. Lipworth B., Kuo C.R., Jabbal S. Current appraisal of single inhaler triple therapy in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 3003–3009. DOI: 10.2147/COPD.S177333.

27. Suissa S., Patenaude V., Lapi F., Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013; 68 (11): 1029–1036. DOI: 10.1136/thoraxjnl-2012-202872.

28. Horita N., Goto A., Shibata Y. et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable сhronic оbstructive рulmonary disease (COPD). Cochrane Database Syst. Rev. 2017; (2): CD012066. DOI: 10.1002/14651858.CD012066.pub2.

29. Vogelmeier C.F., Criner G.J., Martinez F.J. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Arch. Broncoрneumol. 2017; 53 (3): 128–149. DOI: 10.1016/j.arbres.2017.02.001.

30. Crim C., Dransfield M.T., Bourbeau J. et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann. Am. Thorac. Soc. 2015; 12 (1): 27–34. DOI: 10.1513/AnnalsATS.201409-413OC.

31. Rossi A.P., Zanardi E., Zamboni M., Rossi A. Optimizing treatment of elderly COPD patients: what role for inhaled corticosteroids? Drugs Aging. 2015; 32 (9): 679–687. DOI: 10.1007/s40266-015-0291-8.

32. Finney L., Berry M., Singanayagam A. et al. Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease. Lancet Respir. Med. 2014; 2 (11): 919–932. DOI: 10.1016/S2213-2600(14)70169-9.

33. Price D., Yawn B., Brusselle G., Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim. Care Respir. J. 2013; 22 (1): 92–100. DOI: 10.4104/pcrj.2012.00092.

34. Peter M.A. Inhaled corticosteroids as a cause of CAP. Eur. Respir. Monogr. 2014; (63): 234–242. DOI: 10.1183/1025448x.erm6314.

35. Malo de Molina R., Mortensen E.M., Restrepo M.I. et al. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalized with pneumonia. Eur. Respir. J. 2010; 36 (4): 751–757. DOI: 10.1183/09031936.00077509.

36. Dong Y.H., Chang C.H., Lin Wu F.L. et al. Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: a systematic review and meta-analysis of randomized controlled trials. A systematic review and meta-analysis of randomized controlled trials. Chest. 2014; 145 (6): 1286–1297. DOI: 10.1378/chest.13-2137.

37. Chung W.S., Chen Y.F., Hsu J.C. et al. Inhaled corticosteroids and the increased risk of pulmonary tuberculosis: a population-based case-control study. Int. J. Clin. Pract. 2014; 68 (10): 1193–1199. DOI: 10.1111/ijcp.12459.

38. Brode S.K., Michael A., Campitelli M.A. et al. The risk of mycobacterial infections associated with inhaled corticosteroid use. Eur. Respir. J. 2017; 50 (3): 1700037. DOI: 10.1183/13993003.00037-2017.

39. Andréjak C., Nielsen R., Thomsen V.Ø. et al. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax. 2013; 68 (3): 256–262. DOI: 10.1136/thoraxjnl-2012-201772.

40. Huang K., Kuan Y., Chi N. et al. Chronic obstructive pulmonary disease is associated with increased recurrent peptic ulcer bleeding risk. Eur. J. Int. Med. 2017; (37): 75–82. DOI: 10.1016/j.ejim.2016.09.020.

41. Miller D.P., Watkins S., Sampson T., Davis K.J. Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of cataracts and glaucoma among chronic obstructive pulmonary disease patients in the UK General Practice Research Database. Int. J. Chron. Obstruct. Pulmon. Dis. 2011; (6): 467–476. DOI: 10.2147/COPD.S14247.

42. Weatherall M., Clay J., James K. et al. Dose-response relationship of inhaled corticosteroids and cataracts: a systematic review and meta-analysis. Respirology. 2009; 14 (7): 983–990. DOI: 10.1111/j.1440-1843.2009.01589.x.

43. Zervas E., Samitas K., Gaga M. et al. Inhaled corticosteroids in COPD: pros and cons. Curr. Drug. Targets. 2013; 14 (2): 192–224. DOI: 10.2174/1389450111314020006.

44. Suissa S., Kezouh A., Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am. J. Med. 2010; 123 (11): 1001–1006. DOI: 10.1016/j.amjmed.2010.06.019.

45. Matera M.G., Cardaci V., Cazzola M., Rogliani P. Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. Expert Opin. Drug Saf. 2015; 14 (4): 533–541. DOI: 10.1517/14740338.2015.1001363.

46. Herth F., Bramlage P., Muller-Wieland D. Current perspectives on the contribution of inhaled corticosteroids to an increased risk for diabetes onset and progression in patients with chronic obstructive pulmonary disease. Respiration. 2015; 89 (1): 66–75. DOI: 10.1159/000368371.

47. Ernst P., Coulombe J., Brassard P., Suissa S. The risk of sepsis with Inhaled and oral corticosteroids in patients with COPD. COPD. 2017; 14 (2): 137–142. DOI: 10.1080/15412555.2016.1238450.


Дополнительные файлы

Для цитирования: Лещенко И.В. Возможности и ограничения применения ингаляционных глюкокортикостероидов в терапии хронической обструктивной болезни легких.  Пульмонология. 2018;28(5):602-612. https://doi.org/10.18093/0869-0189-2018-28-5-602-612

For citation: Leshchenko I.V. Possibilities and limitations of inhaled corticosteroids in the treatment of chronic obstructive pulmonary disease. Russian Pulmonology. 2018;28(5):602-612. (In Russ.) https://doi.org/10.18093/0869-0189-2018-28-5-602-612

Просмотров: 168

Обратные ссылки

  • Обратные ссылки не определены.


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)